Cocoon Biotech, Inc., was founded in 2013 to bring the freedom of living a healthy productive life to patients worldwide initially through treatments for osteoarthritis. Cocoon Biotech’s platform technology is biocompatible silk fibroin that can be loaded with small molecule or protein therapeutics and injected into joints to provide effective long lasting pain relief. This platform will leverage several unique properties of the silk protein fibroin, including strength, lubrication, and biocompatibility. Our mission is to use this technology to significantly improve the treatment of osteoarthritis and other large unmet medical needs. The osteoarthritis treatment gap alone is currently quite large and new approaches that address both symptoms and disease progression are an urgent need.
The company has completed seed financing and has begun testing prototype products in the laboratory.